Maternal immunization with pneumococcal 9-valent conjugate vaccine and early infant otitis media |
| |
| Affiliation: | 1. Department of Otolaryngology, University of Minnesota Medical School, Minneapolis, MN, USA;2. Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA;3. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA;4. HealthPartners Research Foundation, Minneapolis, MN, USA;5. Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, MN, USA;1. Unidad de Infectología, Hospital General de Agudos Cosme Argerich, Buenos Aires, Argentina;2. Servicio de Neonatología, Hospital General de Agudos Cosme Argerich, Buenos Aires, Argentina;1. Department of Electrical and Computer Engineering, New Jersey Institute of Technology, Newark, NJ 07102, USA;2. National Research Council, Ottawa, ON, Canada KIA 0R6;1. Cancer Prevention Training Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, United States;2. Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, United States;3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States;4. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States;1. Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium;3. Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BIOSTAT), Hasselt University, Hasselt, Belgium;4. Centre for Health Economics Research and Modeling Infectious Diseases, Vaccine and Infectious Disease Institute, University of Antwerp, Belgium |
| |
| Abstract: | A randomized trial of an investigational 9-valent pneumococcal conjugate vaccine (PCV-9) or placebo given to pregnant women during the last trimester to prevent early infant otitis media (OM) was conducted. All infants received Prevnar® at 2, 4, 6, and 12 months. Clinic and adverse event records were reviewed to identify OM. Variables significantly related to acute OM by age 6 months (p < 0.05) were: vaccine group (9 valent or placebo), sibling history of tympanostomy tubes, upper respiratory infection, and number of clinic visits by 6 months. Infant OM rates were similar between 6 and 12 months (58% and 56%). Results suggested that immunizing pregnant women with PCV-9 increased infants’ risk of acute OM in the first 6 months of life, and this correlated with decreased infant antibody responses to their infant Streptococcus pneumoniae vaccine serotypes, but did not influence antibody responses to 3 other serotypes two of which were in maternal vaccine (types 1 and 5) and one was a control (type 7F). Explanations for these results include dampening of infant antibody production by high levels of passively acquired maternal pneumococcal antibodies and/or altered B lymphocyte immune responses in infants exposed to these specific polysaccharide antigens in utero. |
| |
| Keywords: | Pneumococcus Otitis media Maternal immunization Pneumococcal antibodies |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
